Quarterly report pursuant to Section 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.7.0.1
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Net loss $ (3,784,777) $ (1,533,117)  
Cash flows from operations 25,587 (112,258)  
Cash equivalents 0   $ 0
Cash in excess of FDIC limits 308,399    
Allowance for doubtful accounts 100,000   100,000
Shipping and handling 157,359 86,291  
Allowance for customer returns 0 0  
Inventory, noncurrent 5,775,345   6,478,727
Depreciation expense 47,525 49,025  
Research and development 188,716 141,813  
Advertising expense 66,900 67,821  
Unrecognized tax benefits $ 0   $ 0
Warrants outstanding 2,100,000    
Germany and The Netherlands [Member]      
Inventory, noncurrent $ 680,515    
Options and RSU's [Member]      
Stock options outstanding that are antidilutive 16,475,222    
Consumer Products [Member]      
Research and development $ 49,033 141,813  
Specialty Pharmaceuticals [Member]      
Research and development $ 139,683 $ 0  
Accounts Receivable [Member] | One Customer [Member]      
Concentration risk percentage 35.00%    
Accounts Receivable [Member] | Two Customers [Member]      
Concentration risk percentage     58.00%